U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H30F3NO3.ClH
Molecular Weight 413.903
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMISELIMOD HYDROCHLORIDE

SMILES

Cl.CCCCCCCOC1=CC=C(CCC(N)(CO)CO)C=C1C(F)(F)F

InChI

InChIKey=GEDVJGOVRLHFQG-UHFFFAOYSA-N
InChI=1S/C19H30F3NO3.ClH/c1-2-3-4-5-6-11-26-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-25;/h7-8,12,24-25H,2-6,9-11,13-14,23H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula C19H30F3NO3
Molecular Weight 377.4416
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Amiselimod (MT-1303) is a selective sphingosine 1-phosphate 1 (S1P1 ) receptor modulator which is currently being developed for the treatment of various autoimmune diseases. Unlike some other S1P receptor modulators, amiselimod seemed to show a favourable cardiac safety profile in preclinical, phase I and II studies. Amiselimod may be potentially useful for treatment of multiple sclerosis; inflammatory diseases; autoimmune diseases; psoriasis and inflammatory bowel diseases. Amiselimod is currently being developed by Mitsubishi Tanabe Pharma Corporation.

Approval Year

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk.
2017 Jan
Evaluation and Optimization of in silico designed Sphingosine-1-Phosphate (S1P) Receptor Subtype 1 Modulators for the Management of Multiple Sclerosis.
2017 Mar
Patents

Patents

Sample Use Guides

A total of 81 healthy subjects aged 18-55 years were equally randomized to receive amiselimod 0.4 mg, amiselimod 0.8 mg, placebo or fingolimod 0.5 mg once daily for 28 days.
Route of Administration: Oral
HEK293 cells or HCMs were plated onto 48-well culture plates, cultured overnight and then incubated with 100 nmol/L of amiselimod for 3–12 h.
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:34:56 GMT 2023
Edited
by admin
on Sat Dec 16 01:34:56 GMT 2023
Record UNII
AY898D6RU1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMISELIMOD HYDROCHLORIDE
USAN   WHO-DD  
USAN  
Official Name English
Amiselimod hydrochloride [WHO-DD]
Common Name English
2-AMINO-2-(2-(4-HEPTYLOXY-3-TRIFLUOROMETHYLPHENYL)ETHYL)PROPANE-1,3-DIOL HYDROCHLORIDE
Systematic Name English
1,3-PROPANEDIOL, 2-AMINO-2-(2-(4-(HEPTYLOXY)-3-(TRIFLUOROMETHYL)PHENYL)ETHYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
MT-1303
Code English
AMISELIMOD HYDROCHLORIDE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C574
Created by admin on Sat Dec 16 01:34:56 GMT 2023 , Edited by admin on Sat Dec 16 01:34:56 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C142922
Created by admin on Sat Dec 16 01:34:56 GMT 2023 , Edited by admin on Sat Dec 16 01:34:56 GMT 2023
PRIMARY
CAS
942398-84-7
Created by admin on Sat Dec 16 01:34:56 GMT 2023 , Edited by admin on Sat Dec 16 01:34:56 GMT 2023
PRIMARY
PUBCHEM
67418070
Created by admin on Sat Dec 16 01:34:56 GMT 2023 , Edited by admin on Sat Dec 16 01:34:56 GMT 2023
PRIMARY
USAN
CD-124
Created by admin on Sat Dec 16 01:34:56 GMT 2023 , Edited by admin on Sat Dec 16 01:34:56 GMT 2023
PRIMARY
FDA UNII
AY898D6RU1
Created by admin on Sat Dec 16 01:34:56 GMT 2023 , Edited by admin on Sat Dec 16 01:34:56 GMT 2023
PRIMARY
ChEMBL
CHEMBL3707375
Created by admin on Sat Dec 16 01:34:56 GMT 2023 , Edited by admin on Sat Dec 16 01:34:56 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY